IBRX Relative Valuation
IBRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IBRX is overvalued; if below, it's undervalued.
Historical Valuation
Immunitybio Inc (IBRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.80. The fair price of Immunitybio Inc (IBRX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.20
Fair
-6.48
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Immunitybio Inc. (IBRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-11.11
EV/EBIT
Immunitybio Inc. (IBRX) has a current EV/EBIT of -11.11. The 5-year average EV/EBIT is -10.76. The thresholds are as follows: Strongly Undervalued below -24.68, Undervalued between -24.68 and -17.72, Fairly Valued between -3.80 and -17.72, Overvalued between -3.80 and 3.16, and Strongly Overvalued above 3.16. The current Forward EV/EBIT of -11.11 falls within the Historic Trend Line -Fairly Valued range.
12.66
PS
Immunitybio Inc. (IBRX) has a current PS of 12.66. The 5-year average PS is 9324.96. The thresholds are as follows: Strongly Undervalued below -25562.57, Undervalued between -25562.57 and -8118.80, Fairly Valued between 26768.73 and -8118.80, Overvalued between 26768.73 and 44212.49, and Strongly Overvalued above 44212.49. The current Forward PS of 12.66 falls within the Historic Trend Line -Fairly Valued range.
-10.92
P/OCF
Immunitybio Inc. (IBRX) has a current P/OCF of -10.92. The 5-year average P/OCF is -4.24. The thresholds are as follows: Strongly Undervalued below -12.63, Undervalued between -12.63 and -8.43, Fairly Valued between -0.05 and -8.43, Overvalued between -0.05 and 4.15, and Strongly Overvalued above 4.15. The current Forward P/OCF of -10.92 falls within the Undervalued range.
-10.32
P/FCF
Immunitybio Inc. (IBRX) has a current P/FCF of -10.32. The 5-year average P/FCF is -10.00. The thresholds are as follows: Strongly Undervalued below -25.66, Undervalued between -25.66 and -17.83, Fairly Valued between -2.16 and -17.83, Overvalued between -2.16 and 5.67, and Strongly Overvalued above 5.67. The current Forward P/FCF of -10.32 falls within the Historic Trend Line -Fairly Valued range.
Immunitybio Inc (IBRX) has a current Price-to-Book (P/B) ratio of -4.13. Compared to its 3-year average P/B ratio of -4.05 , the current P/B ratio is approximately 2.02% higher. Relative to its 5-year average P/B ratio of -9.04, the current P/B ratio is about -54.26% higher. Immunitybio Inc (IBRX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -21.42%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -18.15% , the current FCF yield is about -100.00% lower.
-4.32
P/B
Median3y
-4.05
Median5y
-9.04
-14.99
FCF Yield
Median3y
-21.42
Median5y
-18.15
Competitors Valuation Multiple
The average P/S ratio for IBRX's competitors is 0.00, providing a benchmark for relative valuation. Immunitybio Inc Corp (IBRX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 425.07%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IBRX decreased by 10.16% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 6.11M to 32.06M.
The secondary factor is the Margin Expansion, contributed -85.06%to the performance.
Overall, the performance of IBRX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Immunitybio Inc (IBRX) currently overvalued or undervalued?
What is Immunitybio Inc (IBRX) fair value?
How does IBRX's valuation metrics compare to the industry average?
What is the current P/B ratio for Immunitybio Inc (IBRX) as of Dec 05 2025?
What is the current FCF Yield for Immunitybio Inc (IBRX) as of Dec 05 2025?
What is the current Forward P/E ratio for Immunitybio Inc (IBRX) as of Dec 05 2025?